Clinical trial NCT00676728: A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome
Official title: A Phase 1 Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Subjects With Advanced or Refractory Leukemia or Myelodysplastic Syndrome
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Advanced or Refractory Leukemia
Myelodysplastic Syndromes
Keywords: Advanced or Refractory Leukemia
Myelodysplastic Syndromes
JNJ 26481585
Histone-Deacetylase Inhibitor
Advanced Leukemia
Refractory Leukemia
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor class: INDUSTRY
First posted: 2008-05-13
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to explore the safety, pharmacokinetic (what the body does to the medication), pharmacodynamic (what the medication does to the body), and activity of JNJ-26481585 in patients with advanced or refractory leukemia and myelodysplastic syndrome (MDS).

Detailed description: This is an open-label (all people know the identity of the intervention), Phase 1 dose escalation, 2-part study (Part I and Part II). In Part I of the study, the Maximum Tolerated Dose (MTD) defined as the highest dose with an observed incidence of dose limiting toxicity (DLT) in no more than 1 in 6 patients, will be determined using rapid escalation (Stage 1) followed by conventional escalation (Stage 2). In Stage 1, at least 2 patients will be enrolled at each dose level; dose increments of 100% will be applied. In Stage 2, at least 3 patients will be enrolled at each dose level and dose increments of 20-50% will be implemented. Decisions on dose escalation or de-escalation, changes in the timing of pharmacokinetic/pharmacodynamic sampling, and the exploration of an alternative schedule were to be made by the Study Evaluation Team (SET), which consisted of all principal investigators, the medical monitor, and 1 of the sponsor's clinical pharmacologists. Part II of the study will be the expansion phase, which will begin after the MTD had been determined in Part I and an additional cohort of patients with MDS will be enrolled to further explore the safety and activity of JNJ 26481585 in patients with MDS. The starting dose for patients enrolled in Part II of the study was to be the MTD established in Part I. Depending on the outcome, the SET may decide to continue at the MTD dose, or dose-de-escalate to the next lower level (25 50% decrement from MTD). The cohort for MDS will be expanded to consist of 16 evaluable patients. Safety will be evaluated throughout the study and will include evaluations of adverse events clinical laboratory tests, electrocardiogram (ECG), vital signs, 24 hours Holter ECG, physical examination, Eastern Cooperative Oncology Group performance status and Multiple Gated Acquisition scan or echocardiography.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed advanced or refractory acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia in blast phase, refractory chronic lymphocytic leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia
* For Part II, patients with myelodysplastic syndrome
* Eastern Cooperative Oncology Group Performance Status Score 0, 1 or 2
* Left Ventricular Ejection Fraction greater than or equal to 50%
* Negative hepatitis B, C and human immunodeficiency virus (HIV) test within last 3 months
* Adequate liver and kidney function

Exclusion Criteria:

* Known or suspected involvement of the central nervous system
* Chemotherapy (nitrosoureas and mitomycin C within 6 weeks), radiotherapy, immunotherapy or treatment with investigative agent within 3 weeks before study drug administration (except hydroxyurea which should be stopped at least 24 hours prior to first dose)
* Unstable angina or myocardial infarction within the preceding 12 months; congestive heart failure
* Poorly controlled hypertension or diabetes, ongoing active infection and psychiatric illness
* Receiving medications known to have a risk of causing QTc prolongation

Primary outcomes:
measure: Number of patients with adverse events
timeFrame: Upto 14 days after last dose administration of study medication
measure: Number of patients with dose limiting toxicity [DLT]
timeFrame: From the date of dosing upto 3 months after the date the last patient enrolled in Part I of the study, received the first dose of study medication
measure: Maximum tolerated dose (MTD) of JNJ 26481585
timeFrame: From the date of dosing upto 3 months after the date the last patient enrolled in Part I of the study, received the first dose of study medication
Secondary outcomes:
measure: Maximum plasma concentration (Cmax) of JNJ 26481585
timeFrame: Days 1, 2, 8, 15 and 21 of Cycle 1
measure: Time to reach maximum plasma concentration (tmax) of JNJ-26481585
timeFrame: Days 1, 2, 8, 15 and 21 of Cycle 1
measure: Area under the plasma concentration-time curve from time 0 to 24 hours (AUC0-24)
timeFrame: Days 1, 2, 8, 15 and 21 of Cycle 1
measure: Elimination half-life (t1/2) of JNJ-26481585
timeFrame: Days 1, 2, 8, 15 and 21 of Cycle 1
measure: Cumulative amount of drug excreted in urine over 24 hours (Ae24)
timeFrame: Days 1 and 21 of Cycle 1
measure: Renal clearance (CLR) of JNJ 26395018
timeFrame: Days 1 and 21 of Cycle 1
measure: Concentration of biomarker histone acetylation
timeFrame: Days 1 and 21 of Cycle 1; Day 21 of Cycles 2 to 20
measure: Concentration of biomarker interleukin-6 (IL-6)
timeFrame: Days 1 and 21 of Cycle 1; Day 21 of Cycles 2 to 20
measure: Concentration of biomarker heat shock protein 90 (Hsp90)
timeFrame: Days 1 and 21 of Cycle 1; Day 21 of Cycles 2 to 20
measure: Complete Blood Count (CBC)
timeFrame: Pre-treatment (within 4 weeks prior to first dose of JNJ-26481585); Days 1, 3, 8, 15 and 21 of Cycle 1; Days 8, 15 and 21 of Cycle 2; Day 21 of Cycle 3 to 20; follow up (within 14 days after last dose of JNJ-26481585)
measure: Assessment of Transfusion Record
timeFrame: From Day 1 of Cycle 1 upto 14 days after last dose
measure: Radiological Tumor Mass assessment
timeFrame: Pre-treatment, Day 21 of Cycle 2 to 20 and follow up
measure: Bone marrow aspirate/biopsy assessment
timeFrame: Pre-treatment, Day 21 of Cycles 1 to 20
Other outcomes:
Locations:
city: Baltimore
country: United States
state: Maryland
city: Houston
country: United States
state: Texas
Study officials:
affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
name: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
role: STUDY_DIRECTOR
References: